Chronic Heart Failure: PBAC Recommends Empagliflozin

By HEOR Staff Writer

April 14, 2023

Introduction:

The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC) decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive nature adequately. A price reduction and risk sharing arrangement were required.

The PBAC has recommended an extension to the current empagliflozin listing on an updated addendum. This extension will include a General Schedule Authority Required (Streamlined) listing. It will be for the treatment of chronic heart failure in patients. These patients have a left ventricular ejection fraction greater than 40%. This recommendation comes after the sponsor addressed the outstanding issues. Also, the cost-effectiveness of the treatment is acceptable at the proposed price.

Empagliflozin’s Efficacy:

The PBAC observed a significant improvement in efficacy when adding Empagliflozin to standard care for this patient group. They based this observation on the primary composite outcome in EMPEROR-Preserved studies. These studies measured the time to the first cardiovascular death or hospitalisation for heart failure.

Addressing Outstanding Issues:

In conclusion, the sponsor has addressed significant outstanding issues identified in the November 2022 PBAC meeting. This was achieved through a proposed price reduction and risk sharing arrangement. The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Empagliflozin would be acceptable at the revised offer price of 16 December 2022.

Reference url

Recent Posts

Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Survival

By João L. Carapinha

October 3, 2025

What is the impact of Enhertu breast cancer treatment for patients with early-stage HER2-positive breast cancer? Enhertu breast cancer treatment has shown a significant improvement in invasive disease-free survival (iDFS) compared to the prior standard, trastuzumab emtansine (T-DM1). According to...
Transforming Healthcare with the Gene Therapy Access Model

By HEOR Staff Writer

October 1, 2025

The gene therapy access model is a groundbreaking federal-state collaborative framework designed to improve how transformative treatments are distributed and financed, particularly within Medicaid. This innovative approach answers a key question for patients and policymakers: How can we ensur...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025

By HEOR Staff Writer

September 29, 2025

Are you searching for effective Sanofi insulin savings options to manage diabetes medication costs in 2025? The Sanofi Patient Connection Savings Registration program offers an efficient pathway for eligible patients to save on key insulin products—helping reduce out-of-pocket expenses and promot...